First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Wolfgang JanniEmilio AlbaThomas BachelotSami DiabMiguel Gil-GilThaddeus J BeckLarisa RyvoRafael LopezMichaela TsaiFrancisco J EstevaPilar Zamora AuñónZdenek KralPatrick WardPaul RichardsTimothy J PluardSantosh SutradharMichelle MillerMario CamponePublished in: Breast cancer research and treatment (2018)
RIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2- ABC.